The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesELISA: 1/10000.
IHC-P: 1/50 - 1/100. Antigen retrieval method: sodium citrate buffer (pH 6.0)
WB: 1/500 - 1/1000. Detects a band of approximately 92 kDa (predicted molecular weight: 92 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionRequired for anchoring microtubules to the centrosomes.
Tissue specificityUbiquitous. Highly expressed in heart, liver, muscle, kidney, intestine, colon, adrenal gland, prostate, testis, and pancreas.
Involvement in diseaseNote=A chromosomal aberration involving FGFR1OP may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity.
Sequence similaritiesBelongs to the FGFR1OP family. Contains 1 LisH domain.
Cellular localizationCytoplasm > cytoskeleton > centrosome. Associated with gamma-tubulin.
ab53071 at 1/50 dilution staining FGFR1 in human breast carcinoma by Immunohistochemistry, Paraffin embedded tissue, in the absence and presence of the immunising peptide.
References for Anti-FGFR1 Oncogene Partner antibody (ab53071)
This product has been referenced in:
Tarkkonen KM et al. Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. PLoS One7:e49970 (2012).
Read more (PubMed: 23185502) »